She Pays Me, She Pays Me Not
Research - In the last 3 trading days, preferred shares of Fortress Bio (FBIOP) have traded down 53% from ~$17 to ~$8. The decline seems to be … Continue Reading
PremiumMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Modular Medical (MODD) Transcript at Sidoti Microcap Conference
Interviews - Mitra Ramgopal Okay, good afternoon, everyone, and welcome to the Sidoti August Microcap Virtual Investor Conference. My name is Mitra Ramgopal. I’m happy to be … Continue Reading
Read nowThe First Seismic Shift Transformed Diabetes Care. A Second is Underway
Insights - The first seismic shift in diabetes care played out during the last six years when continuous glucose monitoring (CGM) became a norm for diabetes patients … Continue Reading
Read now
Transcript of Delcath (DCTH) Call on FDA Approval of Hepzato Kit
Transcripts - Operator Welcome to the Delcath Systems Business Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn … Continue Reading
Read now
KOLs Supportive of GOSS Data & Position in PAH Market
Insights - Last week, Gossamer (GOSS) hosted a KOL call to discuss their Phase 2 results, OLE data and upcoming Phase 3 design. Below are notes from … Continue Reading
Read nowExperts Discuss Diabetes Care & Insulin Pump Market
Digital Conferences - Call Replay: Transcript of Call: Participants Lane Desborough, KOL Davida Kruger, KOL Jeb Besser, MODD CEO Deniel Mero, PropThink Editor PropThink Good afternoon everyone, welcome … Continue Reading
Read nowTranscript of Gossamer (GOSS) OLE Data Call
Transcripts - Bryan Giraudo Good morning, everyone. Thank you for joining us for our Seralutinib Program update discussion about PROSERA’s Phase III design and interim TORREY results. … Continue Reading
Read now